Literature DB >> 25864928

Management of Polypharmacy in Dialysis Patients.

Wendy L St Peter1,2.   

Abstract

Most patients receiving dialysis have other common chronic conditions in addition to end-stage renal disease, including hypertension, diabetes, cardiovascular disease, and mineral and bone disorder, all of which require long-term medication management. Dialysis patients take an average of 10-12 prescribed and over-the-counter medications from an average of 4.7 prescribers, and an average of 19 pills per day. Thus, reducing polypharmacy is not adequate as a medication therapy goal for these patients. Instead, the dialysis community should focus on ensuring that all patients receive medications that are appropriate, effective, safe and convenient. Barriers to this include a fragmented health care system with inadequate communication between multiple prescribers and pharmacies, and frequent care transitions between ambulatory care sites (dialysis centre, ambulatory primary care practice, ambulatory specialty practice) and the hospital, skilled nursing facility or long-term care facility. Three distinct processes are necessary to prevent and solve the resultant medication-related problems (and reduce polypharmacy). These are medication reconciliation (creating an accurate medication list that reflects all medications the patients is taking and how they are being taken), medication review (evaluating the list for appropriateness, effectiveness, safety and convenience in conjunction with the patient's health status), and ongoing patient-centred medication therapy management (e.g., developing treatment plans centred on each patient's medication-related goals). A team approach including pharmacists as part of the dialysis team with the dialysis facility as the primary medication home is needed.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 25864928     DOI: 10.1111/sdi.12377

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  27 in total

Review 1.  Setting the dry weight and its cardiovascular implications.

Authors:  Arjun D Sinha; Rajiv Agarwal
Journal:  Semin Dial       Date:  2017-06-30       Impact factor: 3.455

2.  Medication Exposure and Health Outcomes in Older Patients with End-Stage Kidney Disease: A Prospective Study Undertaken in New Zealand.

Authors:  Sashika Samaranayaka; Robert J Walker; Ari Samaranayaka; Sarah Derrett; John W B Schollum
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

3.  Effectiveness of using STOPP/START criteria to identify potentially inappropriate medication in people aged ≥ 65 years with chronic kidney disease: a randomized clinical trial.

Authors:  Krystina Parker; Ingrid Bull-Engelstad; Jūratė Šaltytė Benth; Willy Aasebø; Nanna von der Lippe; Morten Reier-Nilsen; Ingrid Os; Knut Stavem
Journal:  Eur J Clin Pharmacol       Date:  2019-07-29       Impact factor: 2.953

4.  Association of Polypharmacy with Kidney Disease Progression in Adults with CKD.

Authors:  Hiroshi Kimura; Kenichi Tanaka; Hirotaka Saito; Tsuyoshi Iwasaki; Akira Oda; Shuhei Watanabe; Makoto Kanno; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-15       Impact factor: 8.237

5.  Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017.

Authors:  Julie M Paik; Min Zhuo; Cassandra York; Theodore Tsacogianis; Seoyoung C Kim; Rishi J Desai
Journal:  Am J Nephrol       Date:  2021-11-23       Impact factor: 3.754

Review 6.  Opioids for chronic pain management in patients with dialysis-dependent kidney failure.

Authors:  William C Becker; Michael J Fischer; Daniel G Tobin; Mark B Lockwood; Paul L Kimmel; Laura M Dember; Nwamaka D Eneanya; Manisha Jhamb; Thomas D Nolin
Journal:  Nat Rev Nephrol       Date:  2021-10-07       Impact factor: 28.314

Review 7.  Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.

Authors:  Joanne Reeve; Michelle Maden; Ruaraidh Hill; Amadea Turk; Kamal Mahtani; Geoff Wong; Dan Lasserson; Janet Krska; Dee Mangin; Richard Byng; Emma Wallace; Ed Ranson
Journal:  Health Technol Assess       Date:  2022-07       Impact factor: 4.106

Review 8.  Medication Reconciliation: The Foundation of Medication Safety for Patients Requiring Dialysis.

Authors:  Jill Frament; Rasheeda K Hall; Harold J Manley
Journal:  Am J Kidney Dis       Date:  2020-09-10       Impact factor: 8.860

9.  Ambulatory Medication Reconciliation in Dialysis Patients: Benefits and Community Practitioners' Perspectives.

Authors:  Jo-Anne S Wilson; Matthew A Ladda; Jaclyn Tran; Marsha Wood; Penelope Poyah; Steven Soroka; Glenn Rodrigues; Karthik Tennankore
Journal:  Can J Hosp Pharm       Date:  2017-12-21

10.  Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?

Authors:  Sophie Liabeuf; Karlijn J Van Stralen; Fergus Caskey; Francesca Tentori; Ronald L Pisoni; Ayesha Sajjad; Kitty J Jager; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2017-10-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.